Study Evaluating the Pharmacokinetics of the Potential Drug Interaction Between HCV-796 and Desipramine

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

August 31, 2007

Study Completion Date

August 31, 2007

Conditions
Healthy
Interventions
DRUG

HCV-796

HCV-796 500mg BID x 14 days

DRUG

Desipramine

"Period 1: Single oral dose of desipramine (50 mg) on day 1. No test article administration on days 2 to 6.~Period 2: Multiple oral doses of HCV-796 (500 mg) every 12 hours on days 1 to 9.~Period 3: Multiple oral doses of HCV-796 (500 mg) every 12 hours on days 10 to 14 and a single oral dose of desipramine (50 mg) on day 10."

Trial Locations (1)

19148

Philadelphia

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

ViroPharma

INDUSTRY

lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00500721 - Study Evaluating the Pharmacokinetics of the Potential Drug Interaction Between HCV-796 and Desipramine | Biotech Hunter | Biotech Hunter